CHEMBIO DIAGNOSTICS INC's ticker is CEMI and the CUSIP is 163572209. A total of 40 filers reported holding CHEMBIO DIAGNOSTICS INC in Q1 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $119,000 | -16.8% | 47,793 | -0.5% | 0.02% | -10.0% |
| Q2 2021 | $143,000 | -15.4% | 48,025 | -0.1% | 0.02% | -23.1% |
| Q1 2021 | $169,000 | -26.2% | 48,072 | -0.1% | 0.03% | -27.8% |
| Q4 2020 | $229,000 | +15.1% | 48,129 | +17.8% | 0.04% | -14.3% |
| Q3 2020 | $199,000 | +49.6% | 40,851 | -0.1% | 0.04% | +31.2% |
| Q2 2020 | $133,000 | -90.9% | 40,882 | -87.3% | 0.03% | -90.0% |
| Q4 2019 | $1,466,000 | -25.5% | 321,394 | -0.0% | 0.32% | -31.1% |
| Q3 2019 | $1,968,000 | +6.6% | 321,500 | +6.0% | 0.47% | +17.1% |
| Q2 2019 | $1,847,000 | +10.1% | 303,289 | +0.4% | 0.40% | +8.7% |
| Q1 2019 | $1,677,000 | -3.0% | 302,127 | -1.0% | 0.37% | -20.4% |
| Q4 2018 | $1,728,000 | -37.4% | 305,222 | +16.0% | 0.46% | -27.6% |
| Q3 2018 | $2,762,000 | -5.7% | 263,065 | -0.3% | 0.64% | -24.9% |
| Q2 2018 | $2,929,000 | +81.5% | 263,894 | +30.8% | 0.84% | +47.0% |
| Q1 2018 | $1,614,000 | – | 201,698 | – | 0.58% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Penbrook Management LLC | 344,060 | $1,634,000 | 1.26% |
| Union Square Park Capital Management, LLC | 400,000 | $1,900,000 | 0.76% |
| P.A.W. CAPITAL CORP | 100,000 | $475,000 | 0.42% |
| PRECEPT MANAGEMENT LLC | 150,000 | $713,000 | 0.29% |
| Newbridge Financial Services Group, Inc. | 73,500 | $349,000 | 0.29% |
| SANDERS MORRIS HARRIS LLC | 183,584 | $990,000 | 0.22% |
| FRIESS ASSOCIATES LLC | 555,000 | $2,636,000 | 0.19% |
| PERRITT CAPITAL MANAGEMENT INC | 30,651 | $146,000 | 0.09% |
| Ikarian Capital, LLC | 219,109 | $1,041,000 | 0.05% |
| SEGALL BRYANT & HAMILL, LLC | 705,823 | $3,352,000 | 0.04% |